Monitor effectiveness of IPO pricing and demand; watch for initiation of Tarsier-04 trial in Q3 2026 and top-line results in 2027. The SPA agreement de-risks the regulatory pathway, but clinical execution and additional capital raises remain key risks.
Executive Summary
Tarsier Pharma, an Israeli late clinical-stage biopharmaceutical company focused on inflammatory ocular diseases, files Amendment No. 2 to its F-1 registration statement for an IPO of 5,000,000 ordinary shares at an estimated price range of $8.00 to $10.00 per share (midpoint $9.00). Net proceeds of approximately $41.0 million will primarily fund the Phase 3 pivotal trial of lead candidate TRS01 for non-infectious anterior uveitis and uveitic glaucoma, NDA preparation, and TRS02 development. The company has a history of losses ($5.07 million in 2025), a going concern risk, and its prior Phase 3 trial missed the primary endpoint, though an FDA SPA agreement supports a new trial design with IOP as the primary endpoint.
Key Financial Metrics
Key Facts
- Offering 5,000,000 ordinary shares at $8.00–$10.00 per share; estimated net proceeds of $41.0 million
- Net loss of $5.07 million for 2025; accumulated deficit of $26.93 million as of Dec 31, 2025
- Going concern risk; existing cash insufficient to fund operations for next 12 months
- Prior Phase 3 TRS4Vision trial missed primary endpoint (ACC=0), but post-hoc IOP data supported SPA agreement with FDA for new pivotal trial (Tarsier-04) with IOP safety as primary endpoint
- Proceeds to fund Tarsier-04 trial, NDA prep ($6M), TRS02 R&D ($4M), and $0.678M CEO loan/deferred comp repayment
Financial Impact
Raises approximately $41.0 million in net proceeds; will require substantial additional funding beyond this offering to complete commercialization
Risk Factors
- Clinical trial failure: prior Phase 3 missed endpoint; new endpoint is safety-based and novel
- Going concern: existing cash + IPO proceeds estimated to fund only ~24 months; significant additional capital needed
- Regulatory: SPA agreement does not guarantee approval; FDA may require more data
- Dilution: substantial dilution to existing shareholders; new investors face 83.6% dilution per share
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001213900-26-066188 |
| Document: ea027016609ex1-1.htm | 0001213900-26-066188 |
| Document: ea027016609ex10-9.htm | 0001213900-26-066188 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 18w ago | F-1/A | — | awaiting T+20 | — | — |
Jun 8, 2026 20w ago | F-1/A | — | awaiting T+20 | — | — |
May 18, 2026 23w ago | F-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers